Ultimovacs ASA banner
U

Ultimovacs ASA
OSE:ULTI

Watchlist Manager
Ultimovacs ASA
OSE:ULTI
Watchlist
Price: 14.5 NOK 0.69% Market Closed
Market Cap: kr293.3m

Wall St Price Targets

ULTI Price Targets Summary
Ultimovacs ASA

There are no price targets for ULTI.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Ultimovacs ASA Competitors:
Price Targets
VINP
Vinci Partners Investments Ltd
43% Upside
AREC
American Resources Corp
186% Upside
MASI
Masimo Corp
0% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Ultimovacs ASA

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Ultimovacs ASA

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
56%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
56%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ULTI's stock price target?
Not Available

ULTI does not have any price targets made by Wall Street professionals.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett